A Phase IIa, single-arm, multi center study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with advanced squamous non-small-cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2019
At a glance
- Drugs Avelumab (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 24 Jan 2019 Planned number of patients changed from 40 to 45.
- 24 Jan 2019 Planned primary completion date changed from 21 Jan 2021 to 25 Jan 2021.
- 03 Dec 2018 Planned End Date changed from 21 Jan 2021 to 25 Jan 2021.